OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy
December 19, 2013 at 08:33 AM EST
OPKO Health (NYSE: OPK ), has completed patient recruitment in the second phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic
